- Home
- Publications
- Publication Search
- Publication Details
Title
Transcription and Translation Inhibitors in Cancer Treatment
Authors
Keywords
-
Journal
Frontiers in Chemistry
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-04-21
DOI
10.3389/fchem.2020.00276
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antisense-Mediated Transcript Knockdown Triggers Premature Transcription Termination
- (2020) Jong-Sun Lee et al. MOLECULAR CELL
- Directed RNase H Cleavage of Nascent Transcripts Causes Transcription Termination
- (2020) Fan Lai et al. MOLECULAR CELL
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
- (2020) Shane G. Poplawski et al. Molecular Therapy-Nucleic Acids
- Roles of EphA1/A2 and ephrin-A1 in cancer
- (2019) Katsuaki Ieguchi et al. CANCER SCIENCE
- Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity
- (2019) Joseph L. Jilek et al. Molecular Therapy-Nucleic Acids
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
- (2019) Lu Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia
- (2019) Ralf Buettner et al. JOURNAL OF CELLULAR PHYSIOLOGY
- mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
- (2019) Tian Tian et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting RNA : A Transformative Therapeutic Strategy
- (2019) Wei Yin et al. CTS-Clinical and Translational Science
- Development of micro RNA ‐based therapeutic approaches for cancer patients
- (2019) Ryou‐u Takahashi et al. CANCER SCIENCE
- Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
- (2019) Johannes Ettl Breast Care
- Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7
- (2019) Shanhu Hu et al. CANCER RESEARCH
- Inhibition of RNA polymerase III transcription by Triptolide attenuates colorectal tumorigenesis
- (2019) Xia Liang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs
- (2019) Laikova et al. MOLECULES
- Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines
- (2019) Emily Linnane et al. NUCLEIC ACIDS RESEARCH
- First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematological Cancers: Results of a Phase I Dose Escalation Study
- (2019) Amit Khot et al. Cancer Discovery
- Epigenetics in cancer therapy and nanomedicine
- (2019) Annalisa Roberti et al. Clinical Epigenetics
- The Potential for microRNA Therapeutics and Clinical Research
- (2019) Johora Hanna et al. Frontiers in Genetics
- Direct Ras G12C inhibitors: crossing the rubicon
- (2019) Colin R. Lindsay et al. BRITISH JOURNAL OF CANCER
- Modulating protein–protein interaction networks in protein homeostasis
- (2019) Mengqi Zhong et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- A patent review of BRAF inhibitors: 2013-2018
- (2019) Peng-Fei Wang et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
- (2019) Xue-hai Liang et al. NUCLEIC ACIDS RESEARCH
- Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
- (2019) Hang Zhao et al. OncoTargets and Therapy
- Bone Marrow Transplantation 1957-2019
- (2019) Elizabeth Simpson et al. Frontiers in Immunology
- Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine
- (2019) Sandro Holzer et al. ACS Chemical Biology
- Gene promoter methylation and cancer: An umbrella review
- (2019) Emmanouil Bouras et al. GENE
- Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment
- (2019) Keiko Yamakawa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
- (2019) Haitang Yang et al. Frontiers in Oncology
- Small molecules targeting HIF-1α pathway for cancer therapy in recent years
- (2019) Wendi Tang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma
- (2019) Antonio Sacco et al. BLOOD
- The Role of Non-coding RNAs in Oncology
- (2019) Frank J. Slack et al. CELL
- Eukaryotic Transcription Turns 50
- (2019) Patrick Cramer CELL
- Local Chromatin Motion and Transcription
- (2019) Michael Babokhov et al. JOURNAL OF MOLECULAR BIOLOGY
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Transcriptional Regulation of Energy Metabolism in Cancer Cells
- (2019) Sara Rodríguez-Enríquez et al. Cells
- FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
- (2019) Isabelle Solassol et al. Biomolecules
- Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
- (2019) Aleix Prat et al. LANCET ONCOLOGY
- Non-canonical transcriptional consequences of BET inhibition in cancer
- (2019) Christopher Letson et al. PHARMACOLOGICAL RESEARCH
- Recent insights into the structure of TFIID, its assembly, and its binding to core promoter
- (2019) Avinash B Patel et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Transcription through the nucleosome
- (2019) Tomoya Kujirai et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Milligram scale production of potent recombinant small interfering RNAs in Escherichia coli
- (2018) Guneet Kaur et al. BIOTECHNOLOGY AND BIOENGINEERING
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation withIn VivoAntitumor Activity
- (2018) Tara L. Peters et al. CLINICAL CANCER RESEARCH
- Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo
- (2018) Qian-Yu Zhang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
- (2018) Laura Graham et al. INVESTIGATIONAL NEW DRUGS
- Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy
- (2018) Pui Yan Ho et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Signaling Pathways Involved in the Regulation of mRNA Translation
- (2018) Philippe P. Roux et al. MOLECULAR AND CELLULAR BIOLOGY
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Roadblocks and resolutions in eukaryotic translation
- (2018) Anthony P. Schuller et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis
- (2018) Kevin J. Frankowski et al. Science Translational Medicine
- Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR
- (2018) Tao Yu et al. ACS Medicinal Chemistry Letters
- Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines
- (2018) Sida Shen et al. ACS Medicinal Chemistry Letters
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
- (2018) Aaron D. Springer et al. Nucleic Acid Therapeutics
- Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint
- (2018) Ting Wei et al. Cell Reports
- Abstract 5789: Discovery of clinical candidate BMS-986158, an oral BET inhibitor, for the treatment of cancer
- (2018) Ashvinikumar V. Gavai et al. CANCER RESEARCH
- HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma.
- (2018) Andreas Pahl et al. JOURNAL OF CLINICAL ONCOLOGY
- Saccharomyces cerevisiae (Baker`s Yeast) as an Interfering RNA Expression and Delivery System
- (2018) Molly Duman-Scheel CURRENT DRUG TARGETS
- c-Met kinase inhibitors: an update patent review (2014-2017)
- (2018) Qing-Wen Zhang et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Arginine Citrullination at the C-Terminal Domain Controls RNA Polymerase II Transcription
- (2018) Priyanka Sharma et al. MOLECULAR CELL
- mTOR as a central hub of nutrient signalling and cell growth
- (2018) Joungmok Kim et al. NATURE CELL BIOLOGY
- RNA therapy: Are we using the right molecules?
- (2018) Ai-Ming Yu et al. PHARMACOLOGY & THERAPEUTICS
- Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
- (2018) Lukasz Skalniak et al. Cancers
- Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models
- (2018) Mei-Juan Tu et al. CANCER LETTERS
- Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance
- (2017) Charlotte E. Johnson et al. Essays in Biochemistry
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
- (2017) A. Robert MacLeod et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia
- (2017) Abhishek Maiti et al. LEUKEMIA & LYMPHOMA
- Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
- (2017) Michael J. Wagner et al. MOLECULAR CANCER THERAPEUTICS
- FDA-Approved Oligonucleotide Therapies in 2017
- (2017) Cy A. Stein et al. MOLECULAR THERAPY
- Making sense of antisense oligonucleotides: A narrative review
- (2017) Neelam Goyal et al. MUSCLE & NERVE
- The chemical evolution of oligonucleotide therapies of clinical utility
- (2017) Anastasia Khvorova et al. NATURE BIOTECHNOLOGY
- Overcoming cellular barriers for RNA therapeutics
- (2017) Steven F Dowdy NATURE BIOTECHNOLOGY
- Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
- (2017) Takao Fujisawa et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
- (2017) Sarah J. Ross et al. Science Translational Medicine
- Molecular Mechanisms of Antisense Oligonucleotides
- (2017) Stanley T. Crooke Nucleic Acid Therapeutics
- Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma
- (2017) Dimpy Koul et al. Oncotarget
- Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models
- (2017) Chao Jian et al. Oncotarget
- Fludarabine Inhibits KV1.3 Currents in Human B Lymphocytes
- (2017) Alicia de la Cruz et al. Frontiers in Pharmacology
- New insights for therapeutic recombinant human miRNAs heterologous production: Rhodovolum sulfidophilum vs Escherichia coli
- (2017) Patrícia Pereira et al. Bioengineered
- Activating the Chromatin by Noncoding RNAs
- (2017) Nihay Laham-Karam et al. ANTIOXIDANTS & REDOX SIGNALING
- Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.
- (2017) H. Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-106: Preclinical, Clinical and Beyond
- (2017) Maen Abdelrahim et al. ONCOLOGY
- Recent progress in development of siRNA delivery vehicles for cancer therapy
- (2016) Hyun Jin Kim et al. ADVANCED DRUG DELIVERY REVIEWS
- RVX-297- a novel BD2 selective inhibitor of BET bromodomains
- (2016) Olesya A. Kharenko et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument
- (2016) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Silvestrol induces early autophagy and apoptosis in human melanoma cells
- (2016) Wei-Lun Chen et al. BMC CANCER
- Bromodomain inhibitors and cancer therapy: From structures to applications
- (2016) Montserrat Pérez-Salvia et al. Epigenetics
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
- (2016) Muhammad S. Beg et al. INVESTIGATIONAL NEW DRUGS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Potent and selective bivalent inhibitors of BET bromodomains
- (2016) Michael J Waring et al. Nature Chemical Biology
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- Aptamers as targeted therapeutics: current potential and challenges
- (2016) Jiehua Zhou et al. NATURE REVIEWS DRUG DISCOVERY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Splice-switching antisense oligonucleotides as therapeutic drugs
- (2016) Mallory A. Havens et al. NUCLEIC ACIDS RESEARCH
- The delivery of therapeutic oligonucleotides
- (2016) Rudolph L. Juliano NUCLEIC ACIDS RESEARCH
- Transcriptional termination in mammals: Stopping the RNA polymerase II juggernaut
- (2016) N. J. Proudfoot SCIENCE
- Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy
- (2016) Yuval Ramot et al. TOXICOLOGIC PATHOLOGY
- Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
- (2016) Yasmin Rosshandler et al. Expert Review of Hematology
- Bioengineered non-coding RNA agent (BERA) in action
- (2016) Zhijian Duan et al. Bioengineered
- Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest
- (2016) Yong Zhao et al. Scientific Reports
- Driver and Passenger Mutations in Cancer
- (2015) Julia R. Pon et al. Annual Review of Pathology-Mechanisms of Disease
- Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth
- (2015) Yong Zhao et al. BIOCHEMICAL PHARMACOLOGY
- The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1
- (2015) Wilhelm Palm et al. CELL
- Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
- (2015) Janice Lu Journal of Hematology & Oncology
- Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F
- (2015) Amanda R Oliveira et al. LABORATORY INVESTIGATION
- Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia
- (2015) Joshua F. Zeidner et al. LEUKEMIA RESEARCH
- AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
- (2015) S. M. Guichard et al. MOLECULAR CANCER THERAPEUTICS
- Architecture of the RNA polymerase II–Mediator core initiation complex
- (2015) C. Plaschka et al. NATURE
- Antisense oligonucleotide–directed inhibition of nonsense-mediated mRNA decay
- (2015) Tomoki T Nomakuchi et al. NATURE BIOTECHNOLOGY
- Clinical experiences with systemically administered siRNA-based therapeutics in cancer
- (2015) Jonathan E. Zuckerman et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting the translation machinery in cancer
- (2015) Mamatha Bhat et al. NATURE REVIEWS DRUG DISCOVERY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications
- (2015) Qiu-Xia Chen et al. NUCLEIC ACIDS RESEARCH
- Minnelide, a novel drug for pancreatic and liver cancer
- (2015) Sulagna Banerjee et al. PANCREATOLOGY
- RNAi and Heterochromatin Assembly
- (2015) Robert Martienssen et al. Cold Spring Harbor Perspectives in Biology
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
- (2015) Lei-lei Fu et al. Oncotarget
- DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response
- (2015) Laureen Colis et al. Oncotarget
- Combined MTOR and autophagy inhibition
- (2014) Reshma Rangwala et al. Autophagy
- A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity
- (2014) Karita Peltonen et al. CANCER CELL
- The basal transcription machinery as a target for cancer therapy
- (2014) Claudia Villicaña et al. Cancer Cell International
- Rapamycin: One Drug, Many Effects
- (2014) Jing Li et al. Cell Metabolism
- Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
- (2014) Michelle R. Arkin et al. CHEMISTRY & BIOLOGY
- Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
- (2014) V. Gandhi et al. CLINICAL CANCER RESEARCH
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species
- (2014) Li Pan et al. NATURAL PRODUCT REPORTS
- RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
- (2014) Andrew L. Wolfe et al. NATURE
- mTORC1-mediated translational elongation limits intestinal tumour initiation and growth
- (2014) William J. Faller et al. NATURE
- Regulation of microRNA biogenesis
- (2014) Minju Ha et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
- (2014) Amanda J. Ward et al. NUCLEIC ACIDS RESEARCH
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
- (2014) Jessica E. Bolden et al. Cell Reports
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- (2013) Q. Liu et al. CANCER RESEARCH
- Cyclin-dependent kinase inhibitors closer to market launch?
- (2013) Hervé Galons et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Targeting long non-coding RNAs in cancers: Progress and prospects
- (2013) Chi Han Li et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
- (2013) Aung Naing et al. INVESTIGATIONAL NEW DRUGS
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emerging drug profile: cyclin-dependent kinase inhibitors
- (2013) James S. Blachly et al. LEUKEMIA & LYMPHOMA
- Protein synthesis rate is the predominant regulator of protein expression during differentiation
- (2013) A. R. Kristensen et al. Molecular Systems Biology
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Efficient and specific gene knockdown by small interfering RNAs produced in bacteria
- (2013) Linfeng Huang et al. NATURE BIOTECHNOLOGY
- RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond
- (2013) Stephane E. Castel et al. NATURE REVIEWS GENETICS
- Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer
- (2013) Takayuki Kogure et al. PLoS One
- Mutant KRAS is a druggable target for pancreatic cancer
- (2013) E. Zorde Khvalevsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
- (2013) S. A. Kang et al. SCIENCE
- Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer
- (2013) Anne Tsao et al. Cancer Medicine
- Transcription-associated histone modifications and cryptic transcription
- (2012) Michaela Smolle et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
- (2012) Megan J. Bywater et al. CANCER CELL
- Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II
- (2012) S. G. Manzo et al. CANCER RESEARCH
- Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
- (2012) Roel H. Wilting et al. DRUG RESISTANCE UPDATES
- A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation
- (2012) J. Pidala et al. HAEMATOLOGICA
- Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma
- (2012) Gerhard Moldenhauer et al. JNCI-Journal of the National Cancer Institute
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
- (2012) Christine Vogel et al. NATURE REVIEWS GENETICS
- Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
- (2012) Mustapha Haddach et al. ACS Medicinal Chemistry Letters
- Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells
- (2011) Sneha V. Gupta et al. AAPS Journal
- Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
- (2011) Meir Wetzler et al. CURRENT PHARMACEUTICAL DESIGN
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological Studies
- (2011) Christina M. Rodrigo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
- (2011) K A Blum et al. LEUKEMIA
- XPB, a subunit of TFIIH, is a target of the natural product triptolide
- (2011) Denis V Titov et al. Nature Chemical Biology
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Transcription Inhibition as a Therapeutic Target for Cancer
- (2011) Christine M. Stellrecht et al. Cancers
- Assessment of the Evolution of Cancer Treatment Therapies
- (2011) Manuel Arruebo et al. Cancers
- 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma
- (2010) J. B. Dennison et al. BLOOD
- Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth
- (2010) Denis Drygin et al. CANCER RESEARCH
- Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells
- (2010) Dayana B. Rivadeneira et al. GASTROENTEROLOGY
- Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies
- (2010) Lisa A. Hammond-Thelin et al. INVESTIGATIONAL NEW DRUGS
- 8-Amino-Adenosine Inhibits Multiple Mechanisms of Transcription
- (2010) J. A. Frey et al. MOLECULAR CANCER THERAPEUTICS
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
- (2010) U. Bogdahn et al. NEURO-ONCOLOGY
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
- Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents
- (2010) Karita Peltonen et al. PLoS One
- No-go decay: a quality control mechanism for RNA in translation
- (2010) Yuriko Harigaya et al. Wiley Interdisciplinary Reviews-RNA
- Characterization of a Ras Mutant with Identical GDP- and GTP-Bound Structures,
- (2009) Bradley Ford et al. BIOCHEMISTRY
- The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
- (2009) David M. Lucas et al. BLOOD
- Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
- (2009) Nahum Sonenberg et al. CELL
- Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression
- (2009) Zhipeng Wang et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:
- (2009) Güliz Gürel et al. JOURNAL OF MOLECULAR BIOLOGY
- Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA
- (2009) S. Vispe et al. MOLECULAR CANCER THERAPEUTICS
- A three-dimensional view of the molecular machinery of RNA interference
- (2009) Martin Jinek et al. NATURE
- Altering Chemosensitivity by Modulating Translation Elongation
- (2009) Francis Robert et al. PLoS One
- Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
- (2009) Regina Cencic et al. PLoS One
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model
- (2008) Marie-Eve Bordeleau et al. JOURNAL OF CLINICAL INVESTIGATION
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
- (2008) Mark E. Kleinman et al. NATURE
- Oncogenes and Cancer
- (2008) Carlo M. Croce NEW ENGLAND JOURNAL OF MEDICINE
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More